Findings

What do systematic reviews say?

2,016 questions · 2,067 findings · 222 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 471 · 22.8%GRADE not reported 108 · 5.2%Very low 570 · 27.6%Low 458 · 22.2%Moderate 363 · 17.6%High 97 · 4.7%

Ceftriaxone vs penicillin G

Clinical cure assessed by RPR decrease · people with neurosyphilis

1 finding from 1 review

Antibiotic therapy for adults with neurosyphilis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 36 participants
Very low

Ceftriaxone vs penicillin G

Adverse events Any untoward medical occurrence regarding medications · people with neurosyphilis

1 finding from 1 review

Antibiotic therapy for adults with neurosyphilis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Very low

Ceftriaxone vs penicillin G

Recurrence of neurosyphilis · people with neurosyphilis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic therapy for adults with neurosyphilis 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ceftriaxone vs penicillin G

Time to recovery · people with neurosyphilis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic therapy for adults with neurosyphilis 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ceftriaxone vs penicillin G

Quality of life · people with neurosyphilis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic therapy for adults with neurosyphilis 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ceftriaxone vs penicillin G

Treatment withdrawal · people with neurosyphilis

It is very uncertain whether ceftriaxone changes withdrawals compared with penicillin G (very low certainty).

1 finding from 1 review

Antibiotic therapy for adults with neurosyphilis 2019 · Cochrane Headline outcomes only
RR 2 [0.42, 9.48]
1 study · 36 participants
Very low

Macrolide+tetracycline vs macrolides

Quality of life, measured by CRQ (dyspnoea, fatigue, emotional function, and mastery subscales) · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 187 participants
Very low

Quinolone vs macrolides

All‐cause mortality · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
GRADE not reported

Quality of life Drug resistance/microbial sensitivity Serious adverse events Lung function Hospitalisations Adverse events/side effects Number of participants colonised with P aeruginosa · patients with chronic obstructive pulmonary disease

The review found no eligible studies for this question.

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Macrolides vs tetracycline

Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease

Macrolide showed no clear difference in number of participants experiencing one or more exacerbations… compared with tetracycline (low certainty).

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
OR 0.44 [0.14, 1.38]
1 study · 50 participants
Low

Macrolides vs tetracycline

All‐cause mortality · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
GRADE not reported

Macrolides vs tetracycline

The review found no eligible studies for this question.

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Macrolide+tetracycline vs macrolides

All‐cause serious adverse events 60 weeks (end of study) · patients with chronic obstructive pulmonary disease

It is very uncertain whether macrolide+tetracycline changes all‐cause serious adverse events 60 weeks (end of study) compared with macrolide (very low certainty).

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
OR 1 [0.52, 1.93]
1 study · 198 participants
Very low

Macrolide+tetracycline vs macrolides

Change in baseline trough FEV1 · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 182 participants
Very low

Macrolide+tetracycline vs macrolides

All‐cause mortality 60 weeks (end of study) · patients with chronic obstructive pulmonary disease

It is very uncertain whether macrolide+tetracycline changes all‐cause mortality 60 weeks (end of study) compared with macrolide (very low certainty).

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
OR 1.63 [0.38, 7.02]
1 study · 198 participants
Very low

Macrolide+tetracycline vs macrolides

Number of people experiencing one or more exacerbations, Drug resistance/microbial sensitivity (as reported by trialists), including emergence of atypical bacteria, Number of participants colonised with Pseudomonas aeruginosa · patients with chronic obstructive pulmonary disease

The review found no eligible studies for this question.

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Quinolone vs tetracycline

Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease

Quinolone showed no clear difference in number of participants experiencing one or more exacerbations… compared with tetracycline (low certainty).

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
OR 0.44 [0.14, 1.38]
1 study · 50 participants
Low

Quinolone vs tetracycline

All‐cause mortality · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 50 participants
GRADE not reported

Quinolone vs tetracycline

The review found no eligible studies for this question.

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Quinolone vs macrolides

Exacerbations (number of people experiencing ≥ 1 exacerbations) · patients with chronic obstructive pulmonary disease

Quinolone showed no clear difference in number of participants experiencing one or more exacerbations… compared with macrolide (low certainty).

1 finding from 1 review

Head‐to‐head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
OR 1 [0.32, 3.1]
1 study · 50 participants
Low